Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025Annual Review of Medicine

CGRP and Migraine: Real World Insights and Future Therapeutic Directions

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAndrew F. RussoEKEric A. Kaiser

Discussion

Loading...

Member takes

Implication

Review reveals the benefits of calcitonin gene-related peptide inhibitors in migraine treatment, indicating emerging use in other disorders.

Key Points

  • Migraine management shows promise with monoclonal antibodies and CGRP inhibitors.
  • Data highlights safety profile but notes some adverse effects reported from treatments.
  • This review discusses therapeutic targeting of calcitonin gene-related peptide in neurological disorders.
  • Future directions may involve combinatorial therapies using neuropeptides and CGRP-focused strategies.

Cite This Study

Russo et al. (2025) studied this question.

synapsesocial.com/papers/692b943e1d383f2b2a378b48https://doi.org/10.1146/annurev-med-050224-111631
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CGRP and Migraine: Real World Insights and Future Therapeutic Directions2025
  2. 2Advances in CGRP therapeutic targets for migraine: where do we stand 5 years later?2026 · 1 citations
  3. 3Optimizing Migraine Therapy: A Comparative Review of Dosage and Tolerability of Calcitonin Gene Related Peptide Antagonists2025
  4. 4Preventive Treatment of Migraine2024 · 15 citations
  5. 5Mechanisms of therapeutic action of monoclonal antibodies to the calcitonin gene-related peptide (CGRP) ligand-receptor system in migraine2025